Comment on "Drug Screening for ALS Using Patient-Specific Induced Pluripotent Stem Cells"

Bilada Bilican, Andrea Serio, Sami J Barmada, Agnes Lumi Nishimura, Gareth J Sullivan, Monica Carrasco, Hemali P Phatnani, Clare A Puddifoot, David Story, Judy Fletcher, In-Hyun Park, Brad A Friedman, George Q Daley, David J A Wyllie, Giles E Hardingham, Ian Wilmut, Steven Finkbeiner, Tom Maniatis, Christopher E Shaw, Siddharthan Chandran

Research output: Contribution to journalLetter

Abstract

Egawa et al. recently showed the value of patient-specific induced pluripotent stem cells (iPSCs) for modeling amyotrophic lateral sclerosis in vitro. Their study and our work highlight the need for complementary assays to detect small, but potentially important, phenotypic differences between control iPSC lines and those carrying disease mutations.
Original languageEnglish
Article number188le2
JournalScience Translational Medicine
Volume5
Issue number188
DOIs
Publication statusPublished - 5 Jun 2013

Keywords

  • Amyotrophic Lateral Sclerosis
  • Drug Evaluation, Preclinical
  • humans
  • induced pluripotent stem cell
  • motor neurons

Fingerprint

Dive into the research topics of 'Comment on "Drug Screening for ALS Using Patient-Specific Induced Pluripotent Stem Cells"'. Together they form a unique fingerprint.

Cite this